Cipla Ltd.

Medicines for Malaria Venture (MMV) has signed collaboration agreements with two Indian pharmaceutical companies, Cipla and Strides Arcolab for the development of rectal artesunate for pre-referral treatment of children with severe malaria.

The collaborations, established under the MMV-led ‘Improving Severe Malaria Outcomes’ project funded by UNITAID, aim to develop a rectal artesunate product for submission to WHO prequalification. Cipla and Strides will each develop a product building on the clinical studies led by TDR, the Special Programme for Research and Training in Tropical Diseases led by the World Health Organization. The goal is to achieve WHO-prequalification of a rectal artesunate product by 2016.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Its portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally.